Author:
Sakura Kazuma,Shintani Yasushi,Okumura Meinoshin
Reference28 articles.
1. Patel MR, Kratzke RA. Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl Res. 2013;161:355–64.
2. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–8.
3. Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol. 2014;4(74):1–11.
4. Smyth Templeton N. Gene and cell therapy: therapeutic mechanisms and strategies. 4th ed. Baton Rouge: CRC Press; 2015.
5. Oldfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL, Anderson WF. Using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Human Gene Ther. 1993;4:39–69.